[MOL] Maxim Pharmaceuticals [01064] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Maxim Pharmaceuticals

Good Morning My Friends,

Seems as though this pharmaceutical company is having some wonderful
successes in the treatment of cancer. This may be of some use to you.

God Bless YOu All,
marty auslander

Title: Maxim Pharmaceuticals


About Maxim Pharmaceuticals

Products & Technologies

Current Clinical Trials

Press Releases

Financial Information

Contact Maxim

Maxim Pharmaceuticals

Maxim Pharmaceuticals:  Extending Life With Quality

axim is developing a new generation of drugs, therapies and vaccines for cancer, infectious diseases and topical disorders. The Company's lead drug candidate, Maxamine, has been shown to more than double patient survival in extensive Phase II cancer trials. The initial launch of the drug in the treatment of malignant melanoma is planned for early 2001. The market launch in malignant melanoma is planned to be followed by launches in acute myelogenous leukemia (AML), renal cell carcinoma and hepatitis C.

Please browse our site to learn more about Maxim, our products, and our current clinical trials. Or contact us for additional information.


FDA Grants Orphan Drug Status to Maxamine® for the Treatment of Malignant Melanoma
MAXIM Pharmaceuticals Announces Pricing of Common Stock Offering
MAXIM Pharmaceuticals Reports Positive Results of Preclinical Studies in Oral Mucositis
Single-Center Preliminary Results from Maxim's Phase III Maxamine® Trial in Malignant Melanoma Submitted to Oncology Conference


About Maxim | Products & Technologies | Current Clinical Trials
Press Releases | Financial Information | Contact Maxim


This report contains forward-looking statements that involve risks and uncertainties. The Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include, but are not limited to, those discussed under "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K for the year ended September 30, 1997 and the Company's Registration Statement on Form S-3 (File No. 333-52403), as amended through the date hereof, as filed with the Securities and Exchange Commission, including the uncertainties associated with clinical trials and product development, the risk that products appearing promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, and the risk that the Company will not obtain marketing approval for its products.

Note: Maxamine, Maxamine Therapy, MaxVax and the Maxim logo are trademarks of the company.


© 1998 - 2000 Maxim Pharmaceuticals
All Rights Reserved.
Taylor & Pond Corporate Communications